Nutriband Inc., a pharmaceutical technology company, is making significant strides in developing an innovative abuse-deterrent transdermal drug delivery system. The company's AVERSA technology represents a potential breakthrough in pharmaceutical safety, targeting drugs with high abuse potential such as fentanyl.
The technology's key innovation lies in its ability to prevent drug abuse, misuse, diversion, and accidental exposure while ensuring that necessary medications remain accessible to patients. Nutriband has secured a robust intellectual property portfolio, with patents granted across multiple countries including the United States, Europe, Japan, Korea, Russia, and others.
Nutriband's business strategy focuses on applying its transdermal technology to existing FDA-approved drugs. By doing so, the company aims to improve medication safety, efficacy, and patient comfort. A significant advantage of this approach is leveraging a limited-development regulatory pathway that potentially reduces the number of clinical trials required for new drug approvals.
The company's lead product is an abuse-deterrent fentanyl patch incorporating AVERSA technology. This development could have far-reaching implications for addressing the ongoing opioid crisis by creating a more controlled and safer method of transdermal drug delivery.
With its broad international patent coverage and innovative approach to pharmaceutical technology, Nutriband is positioning itself as a potential game-changer in drug safety and patient care.
